✦ LIBER ✦

Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia

✍ Scribed by Shaw, Peter J. ;Procopis, Peter G. ;Menser, Margaret A. ;Bergin, Mary ;Antony, Jayne ;Stevens, Michael M.

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 387 KB
Volume: 19
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950190210

No coin nor oath required. For personal study only.

✦ Synopsis

Three of 38 children given high-dose cytosine arabinoside therapy developed a previously undescribed complication. Neurological problems are a frequent occurrence in patients given this therapy, particularly cerebellar ataxia, but the development of bulbar and pseudobulbar palsy has not been reported. In two of these cases, it was sufficiently marked for the course of treatment to be curtailed and occurred at a relatively low cumulative dose of the drug. Neurotoxicity can occur at any time using high-dose cytosine therapy.

📜 SIMILAR VOLUMES

Fatal pulmonary failure complicating hig

Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia

✍ Borje S. Andersson; Cassian Yee; Michael J. Keating; Kenneth B. McCredie; Mario 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 620 KB

Reversible bilateral lateral rectus musc

Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapy

✍ Gerard J. Ventura; Michael J. Keating; Agustin M. Castellanos; J. Peter Glass 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 298 KB 👁 1 views

Acute polyneuropathy after high dose cyt

Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia

✍ Harry Openshaw; Neal E. Slatkin; Anthony S. Stein; David R. Hinton; Stephen J. F 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 699 KB

## BACKGROUND. Peripheral nerve toxicity has been reported but is not a commonly recognized complication of high dose cytosine arabinoside (HDAC) therapy. This study was undertaken to estimate the prevalence and describe the clinical spectrum of acute polyneuropathy associated with HDAC therapy fo

The role of timing of high-dose cytosine

The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia

✍ William G. Woods; Frederick B. Ruymann; Beatrice C. Lampkin; Jonathan D. Buckley 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 809 KB

Treatment of acute nonlymphocytic leukem

Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside

✍ Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 1 views

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours

Subacute pulmonary failure complicating

Subacute pulmonary failure complicating therapy with high-dose ara-C in acute leukemia

✍ Borje S. Andersson; Brad M. Cogan; Michael J. Keating; Elihu H. Estey; Kenneth B 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 1 views